Aroa Biosurgery (ASX:ARX) share price up 14% on strong half

Two key updates in the one announcement for investors to enjoy today.

| More on:
smiling health care workers in a medical setting

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Aroa Biosurgery Ltd (ASX: ARX) share price is climbing in early trade this morning as the company released its preliminary half-year results.

At the time of writing, the surgical technology company's share price is up 14.81% from the market open and changing hands at $1.24 a share.

After a robust first half, Aroa also announced it had also signed a contract extension.

Here are the details on both advancements.

Aroa Biosurgery share price lifts on strong preliminary sales growth in first half

Aroa came out of the reporting period with a healthy set of results, with preliminary unaudited sales revenue of around NZ$17 million.

That represents an approximate 108% year on year growth when neutralising exchange rate effects.

After changes the company made to its sales team to drive more product turnover, the company claims to have grown its earnings substantially over the half-year.

On these two factors, Aroa updated its FY22 product sales guidance and now expects to be at the upper end of previous guidance of NZ$30 million to NZ$33 million.

Aroa will "further assess its FY22 product sales revenue guidance" once it confirms its H1 FY22 revenue, including "the quarterly revenue share from TELA Bio".

Aside from this progress, Aroa also announced it had signed a contract extension for its Myriad products.

The contract is to be rolled over with "leading US group purchasing organisation (PGO)" HealthTrusts Purchasing Group, L.P.

According to the company, approximately 1,500 US hospitals and healthcare systems will have access to its Myriad products as a result of the extension.

To cover the announcement in more detail, Aroa is holding an investor presentation today.

What did management say?

Speaking on the announcement, Aroa Biosurgery CEO Brian Ward said:

It is pleasing to see the momentum that is developing across the AROA product portfolio. The changes we made to our sales team [are] delivering on our expectations for Myriad Matrix, Myriad Morcells and Endoform™. We are also seeing growing demand from TELA Bio, Inc., AROA's sales and distribution partner for OviTex™ products.

Regarding the company's guidance figures, Ward went on to add:

Despite the constraints of COVID-19, the preliminary figures represent a strong revenue result for the half year, exceeding internal forecast expectations. Once unaudited revenue for H1 FY22 is confirmed and the outlook for COVID-19 becomes clearer, we intend to further assess our FY22 product sales revenue guidance.

Aroa Biosurgery share price snapshot

The Aroa Biosurgery share price has gained 16.5% in the past month, however, has had a difficult year to date.

It has only managed to climb 5.6% into the green during this time and is 5% in the red over the last year.

Both of these results have lagged the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% in the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

People sit in rollercoaster seats with expressions of fear, terror and exhilaration as it goes into a steep downward descent representing the Novonix share price in FY22
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the trading week this Friday.

Read more »

Siblings jumping on a trampoline.
Share Gainers

These 3 ASX 200 stocks are charging higher this week. Own any?

Investors have been piling into these ASX 200 stocks this week. But why?

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Domino's, Nick Scali, REA, and Sigma shares are charging higher today

These shares are ending the week on a high. Let's see why investors are bidding them higher today.

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why BWP, Magellan, News Corp, and Winsome shares are pushing higher today

These shares are having a better day than most on Thursday. But why?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX was back in form this hump day...

Read more »

A boy stands firm on a rocky cliff holding a rocket in each hand and looking up toward the sky, anticipating flying into space.
Resources Shares

Up 864% in a year, how this ASX mining stock is primed to keep rocketing in 2025

The ASX mining stock looks to be in a sweet spot amid export bans from China and Russia.

Read more »

Happy coal miner.
Energy Shares

Why are ASX coal shares having such a cracking run today?

The latest salvo in the new American tariff war is benefiting some ASX shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Share Gainers

Why BWP, Insignia, Nufarm, and Pinnacle shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »